News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trevena, Inc. (TRVN) Reports Second Quarter 2014 Financial Results



8/12/2014 8:46:05 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced financial results for the quarter ended June 30, 2014.

“We have continued to make significant progress across all areas of our business to support the advancement of our clinical portfolio and R&D pipeline,” said Maxine Gowen, Ph.D., chief executive officer. “This quarter we initiated an important Phase 2a/b trial for TRV130 in postoperative pain, which we expect to enable Phase 3 development, and we have successfully completed the first portion of the study. We also completed our first clinical study of oral TRV734 for moderate-to-severe pain with very encouraging results, and we remain on track with the BLAST-AHF study of TRV027 in acute heart failure. It has been a very productive quarter and we expect our current momentum to continue as we advance our ongoing clinical trials toward important data milestones over the next several quarters.”

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES